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Abstract
Lymphoblastoid cell lines (LCLs), originally collected as renewable sources of DNA, are now being used as a model system to
study genotype–phenotype relationships in human cells, including searches for QTLs influencing levels of individual mRNAs
and responses to drugs and radiation. In the course of attempting to map genes for drug response using 269 LCLs from the
International HapMap Project, we evaluated the extent to which biological noise and non-genetic confounders contribute
to trait variability in LCLs. While drug responses could be technically well measured on a given day, we observed significant
day-to-day variability and substantial correlation to non-genetic confounders, such as baseline growth rates and metabolic
state in culture. After correcting for these confounders, we were unable to detect any QTLs with genome-wide significance
for drug response. A much higher proportion of variance in mRNA levels may be attributed to non-genetic factors (intra-
individual variance—i.e., biological noise, levels of the EBV virus used to transform the cells, ATP levels) than to detectable
eQTLs. Finally, in an attempt to improve power, we focused analysis on those genes that had both detectable eQTLs and
correlation to drug response; we were unable to detect evidence that eQTL SNPs are convincingly associated with drug
response in the model. While LCLs are a promising model for pharmacogenetic experiments, biological noise and in vitro
artifacts may reduce power and have the potential to create spurious association due to confounding.
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Introduction
Genetic mapping offers an unbiased approach to discover genes
and pathways influencing disease traits and responses to drugs and
environmental exposures [1]. Unlike model organisms that can be
exhaustively phenotyped and readily exposed to drugs and toxins
in the laboratory, there are substantial limits to the phenotypes
that can be safely elicited or measured in human subjects. Thus,
there would be great value in a human in vitro model that
faithfully reflects both in vivo genetics and physiology while
allowing for systematic perturbation and characterization in high
throughput. Such a model would be particularly useful to study the
function of sequence variants mapped by whole genome
association studies of common human diseases that do not fall in
obvious coding sequences [2–6], many of which are presumed to
influence disease traits through subtle effects on gene regulation.
One such model system has been proposed and extensively
studied: EBV-transformed lymphoblastoid cell lines (LCLs)
derived from human B-lymphocytes [7–13]. Lymphoblastoid cell
lines have long been produced as renewable sources of DNA as
part of normal and diseased cohorts. Initially, LCLs derived from
genotyped CEPH pedigrees [14] and HapMap participants [15]
were used to identify genomic regions linked to and associated
with inter-individual variation in mRNA transcript levels (these
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[16–19]. A small number of such eQTLs have been found to also
be associated with human disease [20–22]. LCLs have also been
used to search for genetic variants that predict for response to
radiation and drugs in vitro [23–26]. Some investigators have
performed joint analysis of eQTLs and drug response QTLs,
seeking non-random relationships between genotypes at single
nucleotide polymorphisms (SNPs), baseline mRNA levels, and
response to chemotherapeutic agents [27,28]. One recent study
reported identification of eQTLs that explain up to 45% of the
variation seen between individuals in cell sensitivity to chemo-
therapy [28].
The utility of genetic mapping in LCLs is a function both of
how well LCLs reflect the in vivo biology of the people from whom
they were collected, and the ability to eliminate potential sources
of confounding that could reduce power and cause spurious
associations between cell lines (and the DNA variants they carry)
and traits. While the DNA sequence of an LCL is typically a stable
representation of the human donor [29], relatively less is known
about the stability of cellular traits studied in vitro, and how they
are influenced by non-genetic factors. Certainly, there are many
opportunities for non-genetic factors to be introduced in the path
from the human donor to the study of an LCL in vitro (Figure 1):
the random choice of which subpopulation of B-cells are selected
in the process of immortalization, the amount of and individual
response to the EBV virus, the history of passage in cell culture
and culture conditions, the laboratory protocols and reagents with
which assays are performed, and the measurements used to assess
drug response and mRNA phenotypes.
Encouraged by previous studies and the emerging HapMap
resource, we set out to use LCLs to map genetic contributors to
drug response in LCLs. In the course of this work we examined the
relative contributions of DNA sequence variation, biological (day-
to-day) variability, and confounders such as growth rate, levels of
the EBV virus, ATP levels, and cell surface markers [30]. We
investigated these factors in relation to two classes of phenotypes –
drug response and mRNA expression levels. We find that inter-
individual rank order based on both drug responses and mRNA
expression levels is only modestly reproducible across independent
experiments. Measurable confounders (in vitro growth rate, EBV
copy number, and cellular ATP content) correlate more strongly
and to a larger fraction of traits than do DNA variants. Even after
correcting for confounders, and after integrating both eQTLs and
mRNA correlations to drug response into a single model, we were
unable to find convincing evidence for QTLs associated with drug
response. Our observations suggest that, in addition to larger
sample sizes, careful attention to influences of potential confound-
ers will be valuable in the attempt to perform genetic mapping of
drug responses in LCLs in vitro.
Results
Data Collected
We studied 269 cell lines densely genotyped by the International
HapMap Project [31]. Cell lines were cultured under a structured
protocol and characterized at baseline for a variety of cellular
phenotypes including growth rate, ATP levels, mitochondrial
DNA copy number, EBV copy number, and measures of B-cell
relevant cell surface receptors and cytokine levels. Each cell line
was exposed in 384-well plates to a range of doses for each of seven
drugs selected based on their divergent mechanisms of action and
importance in clinical use for treatment of B-cell diseases, focusing
on anti-cancer agents: 5-fluorouracil (5FU), methotrexate (MTX),
simvastatin, SAHA, 6-mercaptopurine (6MP), rapamycin, and
bortezomib. Drug response was measured using Celltiter Glo, an
ATP-activated intracellular luminescent marker that, when
compared to mock-treated control wells, can represent relative
levels of cellular viability and metabolic activity. Data can be
downloaded from the Broad Institute web site: http://www.broad.
mit.edu/mpg/pubs/hapmap_cell_lines/.
Total RNA was collected at baseline and mRNA transcript
levels (hereafter referred to as ‘‘RNA’’) were measured genome-
wide on the Affymetrix platform. Expression data is available on
GEO Accession # GSE11582. For QC and normalization details,
see Materials and Methods.
Baseline characterization and plating for drug response
experiments was performed in batches of 90 cell lines from each
HapMap analysis panel (CEU, JPT/CHB, and YRI) on each of
three experiment days. The order of cell lines within each panel
was randomized to avoid inducing artificial intra-familial corre-
lation. Each drug was tested at a range of doses around the
expected IC50 as reported for the drug by the NCI DTP; each
dose of drug was tested in two wells per plate and on two separate
plates. These replicate measurements for each cell line allowed
assessment of intra-experimental variation.
To evaluate day-to-day (i.e. inter-experimental) variation in all
traits, a subset of 90 cell lines (30 from each of the three HapMap
panels) was grown from freshly thawed aliquots and the entire
experiment was repeated. To evaluate the effect of technical error
on measured RNA levels, a set of 22 RNAs previously expression
profiled (using Illumina HumanChip) at Wellcome Trust Sanger
Institute (WTSI) was included in expression profiling at the Broad
on Affymetrix arrays.
Cell Line Sensitivity to Chemotherapeutic Drugs
Gene mapping of drug response (or any cellular phenotype) in
LCLs requires that the phenotype be: (1) technically well
measured, (2) biologically reproducible across independent
experiments, and (3) remain relatively free from confounding
factors. We assessed each of these characteristics in turn before
performing genome-wide association scans.
To evaluate variability in drug response across replicate plates
assayed on a given experiment day (technical reproducibility), we
calculated the ‘‘relative’’ response of a cell line to each drug by
Author Summary
The use of lymphoblastoid cell lines (LCLs) has evolved
from a renewable source of DNA to an in vitro model
system to study the genetics of gene expression, drug
response, and other traits in a controlled laboratory
setting. While convincing relationships between SNPs
and mRNA levels (eQTLs) have been described, the degree
to which non-genetic variables also influence phenotypes
in LCLs is less well characterized. In the course of
attempting to map genes for drug responses in vitro, we
evaluated the reproducibility of in vitro traits across
replicates, the impact of the EBV virus used to transform
B cells into cell lines, and the effect of in vitro culture
conditions. We found that responses to at least some
drugs and levels of many mRNAs can be technically well
measured, but vary both across experiments and with non-
genetic confounders such as growth rates, EBV levels, and
ATP levels. The influence of such non-genetic factors can
both decrease power to detect true relationships between
DNA variation and traits and create the potential for non-
genetic confounding and spurious associations between
DNA variants and traits.
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curve for the drug on a given plate to the dose-response curve for
the drug averaged across all cell lines assayed that day, in that
replicate plate set. (The two replicate plates for each cell line
performed on an experiment day were arbitrarily placed into set A
or B.) This non-parametric approach allowed all drugs to be
treated uniformly (see Methods) and generated two data points per
cell line, per drug, per day. We ranked the cell lines based on their
relative response in plate set A and separately based on values
from plate set B. The rank-correlation (Spearman’s rho) for
relative response across sets A and B was high (rho=0.86 to
rho=0.99, Table S1), indicating that drug response on a given day
is both highly reproducible and technically well measured in this
experimental design.
To evaluate variability across independent experiments on
separate days (biological reproducibility), we repeated the assay on
a subset of ,90 cell lines (30 from each of the three HapMap
analysis panels). (At this point, we noted that our assays for
rapamycin and bortezomib suffered from weak responses and
strong dependence on drug batch, respectively, and removed these
drugs from future analysis; see Methods for details). For the
remaining five drugs, cell lines were ranked based on relative
response on day 1 and again on day 2 as above, and the rank-
correlation (Spearman’s rho) was calculated. In comparison to the
high technical reproducibility on a given experimental day, inter-
cell line variability in drug response was much less reproducible
across independent experiments (rho=0.39–0.82, Table S2).
We noted that the rank order of cell lines based on relative drug
response was strikingly similar between three drugs (5FU, 6MP,
and MTX). In fact, the rankings of cell lines based on these three
drugs were as similar to one another as to rankings based on
biological replicates of the same drug on different days (Figure 2A
and Table S3). Wondering if this observation was limited to our
dataset, we examined the publicly available data of Watters et
al.[25] (Figure 2B). We found a very similar correlation of relative
response to a distinct pair of drugs, 5FU and docetaxel, in their
experiments. (This correlation likely explains why these investiga-
tors found linkage for both drugs to the same genomic locus.) Such
a correlation in relative response to multiple drugs could, in
theory, indicate a shared genetic mechanism common to many
drugs, but it could also suggest the influence of an experimental
confounder that more strongly influences drug response than does
genetic variation.
We searched for and identified one such confounder: the
baseline growth rate of the individual cell lines was highly
correlated to the relative responses to these drugs (Figure 2C;
Table S3). Growth-rate was modestly reproducible across days
(rho=0.37), with very limited evidence for heritability (h
2=0.35;
pval=0.08). (We note that our study is not well-powered to detect
h
2,0.5 (Figure S1).) The dependence of drug response on growth
Figure 1. Genetic and non-genetic factors influencing lymphoblastoid cell lines as a model system to understand human
physiology.
doi:10.1371/journal.pgen.1000287.g001
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three agents depend upon cell division. Using a differential
equation model of drug response accounting for the kinetics of
exponential growth under exposure to drug (see Methods), we
estimated a growth rate adjusted EC50 for each cell line for each
of the three affected drugs. This approach removed the bulk of the
Figure 2. Drug response is correlated across multiple drugs, to growth rate and to baseline ATP levels of the cell line. (A) Relative
drug responses were calculated for each individual as described in Methods to obtain a single number summary of the cell line response to each drug
on each day. The black circles represent an individual cell line’s relative response to 6MP assayed on day one plotted against 6MP relative response
assayed on day two. The red circles similarly represent relative response to 6MP plotted against relative response to MTX, both assayed on day one.
The green circles represent relative response to 6MP plotted against relative response to 5FU, again both assayed on day one. Lines represent
regressions for each of the three comparisons and show that not only is relative drug response a reproducible trait, but also can be correlated across
multiple drugs. (B) Using online data made publicly available by Watters et al. [25], relative drug response to docetaxel and 5FU was calculated using
the 427 individuals with no missing data to obtain a single number for each drug, in each individual, as in (A). Response to docetaxel was plotted
against 5FU for each individual. The line represents the regression for the comparison and indicates that the effect observed in (A) is neither limited
to our experiments, nor to the particular drugs we attempted. (C) The baseline growth-rate of each individual’s cell line was estimated as described in
the Methods. This growth rate is plotted against relative response for 6MP (black), MTX (red), and 5FU (green). Lines represent regressions for the
respective comparisons and all correspond to significant correlations. (D) For each individual, baseline ATP levels were measured using Celltiter glo in
the mock-treated wells in drug response assays. EC50 response was calculated correcting for growth rate (see Methods). Relative ATP levels were
plotted against the growth-rate corrected EC50 for MTX (red), and 5FU (green). Lines represent regression for the comparisons and indicate
significant correlations.
doi:10.1371/journal.pgen.1000287.g002
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and growth rate (Table S4), though some correlation of responses
persisted. Standard EC50s were fit for Simvastatin and SAHA.
Given the residual correlation across drugs, we searched for
other non-genetic confounders. Baseline ATP concentrations
(estimated based on the average of Celltiter glo values for all
mock-treated wells, see Methods) were correlated to the growth
rate adjusted EC50s for MTX and 5FU (Figure 2D). Like growth
rate, ATP levels were reproducible across biological replicates
(rho=0.6) without statistically significantly evidence for heritabil-
ity (h
2=0.19, pval=0.12). After further adjusting the growth rate
adjusted EC50s for MTX and 5FU for ATP levels using linear
regression, the correlation across drugs was nearly abrogated
(Table S5).
Having adjusted for confounding due to growth rate and ATP
levels, and largely eliminating correlations across drugs that were
attributable to in vitro rather than inherited influences, we
performed genome-wide association studies. Specifically, we
examined the relationship between the EC50s for each drug and
SNPs from HapMap Phase 2 with Minor Allele Frequency (MAF)
.10% [32]. We did not observe any associations that surpassed
genome wide significance (p-val,5e-8). The study was well
powered to detect only strong QTLs, those that explain .15%
of the variance in drug response (Figure S2). Nonetheless, the
distributions of statistical association between SNPs and EC50s did
not significantly exceed expectation under the null hypothesis. Our
lack of evidence for association between SNPs and drug responses
is consistent with prior publications [24–28], none of which
identified specific SNPs that exceeded genome wide significance.
Variability in RNA Expression
Previous studies observed baseline levels of RNA expression
correlated to response to cisplatin and etoposide [24,27,28]. A
correlation does not imply a causal contribution to drug response,
as a third factor could simultaneously affect both phenotypes.
Nonetheless, in the effort to identify a subset of genes whose
regulation may truly influences drug response, it may be valuable
to integrate information on SNP associations with RNA levels
(eQTLs) and RNA correlations to drug responses. We therefore
turned our attention to RNA measurements in LCLs.
As with drug response, genetic mapping of variants that
influence RNA expression requires that interindividual variation
in RNA levels is (a) reproducible on a given day, (b) reproducible
across experiments performed on different days, and (c) influenced
by genetic variation to a greater extent and independent of
confounding by experimental artifacts.
One common metric for evaluating reproducibility in expres-
sion data is to rank the level of expression of all genes in a given
sample, and to compare these ranks of genes (relative to one
another) to those obtained in a separate hybridization of another
aliquot of the same RNA (technical replicates) or in RNA from the
same cell line on a different day (biological replicates). When we
assessed the reproducibility of ranked RNA levels using this metric,
we observed a high correlation across biological replicates:
(Figure 3A – black curve). Moreover, we observed a similar
correlation between profiles from any pair of unrelated individuals
(Figure 3A – red curve), and across human cell lines in comparison
to those from chimpanzee (Figure 3A – blue curve). What this
reflects is the simple fact that the dynamic range in expression
levels across genes is stable across primates, and much larger in
magnitude than the inter-individual variation in the level of any
given gene.
A more relevant metric for gene mapping is the reproducibility
in rank order of different individuals based on the level of
expression of a given gene. If the level of a single RNA transcript
in one individual is reproducibly higher than the same RNA
transcript in another individual, then it may be possible to identify
genetic variants contributing to inter-individual variation of this
RNA transcript (i.e. an eQTL). In contrast, if variation in the level
of an RNA transcript across individuals is low relative to the
technical and biological noise in a single individual, then there will
be limited power to map genetic influences that alter expression of
the gene.
We examined inter-individual variation in RNA levels for each
of 3,538 genes measured to be expressed in the cell lines (using
standard criteria for expression arrays). The analysis included
LCLs from 49 unrelated individuals that were independently
thawed, cultured and profiled on two different days (Figure 3B). In
contrast to the results in Figure 3A, which showed excellent
technical reproducibility, we see that the rank-correlation of
individuals on different days (based on measured levels of
individual genes) is typically modest (rho=0.25–0.3). That is, in
our experiment, only a fraction of the 3,538 RNA transcripts
examined in LCLs vary reproducibly between individuals relative
to technical and biological noise.
To parse the contributions of technical and biological noise, we
examined the reproducibility of rank orders of cell lines when
aliquots from the same RNA sample were profiled on two different
array platforms. Specifically, RNAs for 14 unrelated individuals
(from YRI HapMap subset) were profiled using the Illumina
system at WTSI, and these same RNA samples were profiled on
Affymetrix microarrays at Broad. To evaluate the contribution of
technical measurement error, we calculated reproducibility in the
rank order of individuals based on these technical replicates. We
observed a median rank-correlation of rho=0.55 (Figure 3C –
gold curve), much higher than the biological reproducibility
observed when two RNA samples for the same 14 individuals were
independently prepared in a single lab and expression profiled on
the same platform (rho,0.3, Figure 3C – green curve). Thus,
biological variation in RNA expression is greater than measure-
ment error, even across different technologies.
To further minimize the impact of technical measurement
error, we henceforth restricted analysis to one thousand genes that
displayed the greatest technical reproducibility in rank ordering
individuals (rho.,0.7, median rho,0.85). Genes excluded by
this threshold include both those that are technically well
measured but invariant across individuals, and those for which
inter-individual variation is obscured by technical noise. (As the
WTSI performed four technical replicates while Broad performed
only a single technical replicate, WTSI data had lower overall
variance.) Genes excluded by this filter typically varied less across
individuals, particularly in the better-measured WTSI dataset.
(median standard deviation of 1000 best-measured genes=0.27 vs
0.17 for the other ,2500 expressed genes; p-val,1e-15).
When analysis was limited to these one thousand genes, the
correlation across biological replicates improved but was still
modest (rho=0.55, Figure 3D – cyan). That is, despite excellent
technical reproducibility overall (Figure 3A) even relative to inter-
individual variation (Figure 3C), the rank order of individuals
based on most genes was only partially reproducible.
We reasoned that some of the biological noise might be due to
other measured factors, as had been the case for drug response.
Using a threshold of 5% variance explained, growth rate was
correlated to levels of expression of only relatively few genes
(,5%). In contrast, ,15% of genes showed correlation to EBV
copy number (Figure 4A), some of which encode genes known to
participate in transduction pathways downstream of EBV
signaling [33,34,35]. Moreover, the level of expression of .25%
Genetic Analysis of In Vitro Traits
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40% of genes have at least 5% of their variation in RNA levels
correlated to one of three confounders above (Figure 4E).
The correlation of RNA levels to such factors could, in
principle, represent intrinsic characteristics of each LCL (which
could potentially be due to inherited DNA sequence variation,
acting indirectly through susceptibility to EBV infection or
inducing a metabolic state). Alternatively, growth rate, EBV
infection, and metabolic state could represent experimental
artifacts that obscures genetic contributions to gene expression
variation. Interestingly, measurements of EBV copy number, ATP
level, and growth rate at Broad correlate to levels of RNA
expression generated independently at WTSI [18,19] (Figure 4F),
albeit more weakly than for the expression profiles generated on
the same samples at the Broad. Thus, these confounders display a
component intrinsic to each cell line, as well as a substantial
component that is not a reproducible attribute of the cell line.
To examine how much of the variability in gene expression
might be demonstrably attributed to inherited DNA variation, we
searched for cis-eQTLs associated with RNA expression levels in
our experiment. Using HapMap Phase 2 SNPs with MAF.10%
that lie within a 0.15 Mb window around each gene, we
performed standard linear regression between expression values
of that gene and SNP genotypes coded 0,1,2 (representing the
number of minor alleles carried by the individual). In our dataset,
,9% of genes harbored a cis-eQTL that explained 5% or more of
the gene’s variance in expression levels (Figure 4C, reporting the
Figure 3. Biological variation in RNA expression. 49 unrelated
individuals were whole-genome RNA profiled on the Affymetrix
platform in two independent experiments at the Broad Institute.
(same-platform biological replicates) A subset of 14 (of the 49) were
also profiled independently at the WTSI on the Illumina platform (cross-
platform biological replicates) and an aliquot of that RNA (‘‘WTSI RNA’’)
was again profiled at the Broad Institute on the Affymetrix platform.
(cross-platform technical replicates) (A) Expression values of all 3538
expressed genes were ranked in each of the 14 unrelated individuals in
the two Broad Institute biological replicate experiments and ranks were
compared between: the same individuals in two separate experiments
(black); all pairs of unrelated individuals across two experiments (red); 5
chimpanzees assayed in the first experiment and all individuals assayed
in the second experiment (blue). Plot shows that overall expression
profiles in LCLs are highly similar across biological replicates, between
unrelated individuals, and even across species. (B) The 49 individuals
were ranked according to their relative levels of each gene in the first
Broad experiment. The ranking was then independently repeated for
the second Broad experiment. Ranks were compared across the two
experiments for each gene and the results plotted in (green), with the
median of the distribution in (dotted green). Plot shows that when any
given gene is examined, there is substantial variation in the relative
order of individuals between two independent experiments, despite the
relative order of genes being highly stable as shown in (A). Light black
and red lines are same as (A) for comparison. (C) On the set of 14
individuals, per-gene rank comparisons as in (B) are computed for: WTSI
RNA assayed on the Illumina platform vs. WTSI RNA assayed on the
Affymetrix platform (gold solid and dotted); WTSI RNA assayed on the
Illumina platform vs. RNA extracted at the Broad Institute during the
first experiment and assayed on the Affymetrix platform (brown solid
and dotted); the two independent Broad experiments as in (B), (green
solid and dotted). Plot shows substantial biological variation in the
relative levels of any given gene when profiling experiments are
repeated, far in excess of that might be expected from measurement
error alone. Magenta dash indicates the cut-off for the 1000 ‘‘technically
best-measured’’ genes to use in (D). (D) The analysis for the brown and
green curve in (C) is repeated only for the 1000 ‘‘best-measured’’ genes
and plotted in magenta and cyan respectively. Plot shows that even if
measurement noise is limited, a substantial portion of the variance in
gene expression represents biological noise.
doi:10.1371/journal.pgen.1000287.g003
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eQTLs were evident in the WTSI expression data (which, due to
the use of four technical replicates, has lower technical noise):
.20% of genes were associated with a SNP that explains 5% or
more of the variance (Figure 4D).
Consistent with previous analyses [16,17,18], in both data sets
only a small fraction of genes displayed a cis eQTL that explained
a large proportion of variance in RNA levels. Moreover, the
fraction of genes that showed correlation to growth rate, EBV, and
ATP substantially exceeded the fraction associated with a cis-
eQTL of the same strength (compare figure 4E to 4C).
Inter- and Intra-Individual Variance Component Analysis
To parse the association of SNPs and other measures with
variation in gene expression, we decomposed the total variance in
expression of each gene into inter-individual and intra-individual
(experimental) variation. As expected, eQTLs contribute only to
inter-individual variation (Figure 5A), while EBV and ATP are
correlated to either inter-individual or intra-individual variation,
depending on the gene (Figure 5B and 5C).
Taken together, these observations have a number of implica-
tions: First, RNA levels for more genes are correlated to the
measured non-genetic cellular factors than are associated with
individual cis-eQTLs. Second, these non-genetic factors may
influence gene expression not only by varying across cell lines in a
reproducible manner (like SNPs), but also by varying across
experiments for the same cell line. Third, for some genes, a given
non-genetic factor is correlated to inter-individual variation (genes
arrayed along the x-axis in Figure 5), and yet for other genes that
same factor is correlated only to intra-individual variation (genes
arrayed along the y-axis). Factors correlated to inter-individual
variation could, in principle, represent processes related to the
action of a genetic variant, whereas those that only vary across
experiments represent noise with respect to genotype-phenotype
association.
Correlation of RNA Levels to Drug Response
We observed a large number of genes whose level of RNA
expression at baseline was correlated to drug response. Levels of
RNA transcripts for 20% of genes in the Broad Institute dataset
and 18% in the WTSI dataset were correlated (at a rho
2.0.05) to
EC50 for at least one of the drugs assayed (after growth-rate and
ATP adjustment). EC50s for SAHA and 5FU appeared to have
the strongest relationship to RNA levels, correlating to 8.7% and
to 7.7% of genes measured at the Broad and WTSI, respectively.
Applying the variance components analysis to see how inter-
and intra- individual variation in growth-rate and ATP adjusted
EC50s are potentially influenced by RNA levels (and ‘‘assigning’’
to a given gene its strongest correlated drug), we observed that
RNA levels are predominantly correlated to inter-individual
differences in EC50s (Figure 5D). Much less of the correlation
between RNA expression and EC50s reflects intra-individual
variation. This observation supports the hypothesis that interin-
dividual variation in RNA levels due to eQTLs may contribute to
variation in drug response.
Integrating Data from eQTLs and Drug Response in LCLs
Having evaluated SNP associations with RNA levels (eQTLs),
and the correlation of RNA levels to drug response, we asked
whether the two relationships might point to eQTL SNPs
associated with drug response. First, we asked whether there was
an enrichment of genes both correlated to drug response and
associated with an eQTL. Second, for the subset of genes with
both an eQTL and correlation of RNA levels to drug response, we
asked whether the eQTL SNPs were associated with drug
response. Finally, we evaluated whether the strength of SNP
association with RNA levels (eQTL) is correlated to the strength of
SNP association with drug response. None of these analyses
strongly supported an influence of eQTL SNPs on drug response.
We first examined the fraction of genes whose expression is
associated with an eQTL and correlated to drug response. As seen
in Figure 4, ,14% and 4.5% of genes have cis-eQTLs (r
2.0.08,
FDR,10%) in the WTSI and Broad Institute datasets respective-
ly. In the same data, levels of RNA of 18% (WTSI) and 20%
(Broad) of genes are correlated to drug response (rho
2.0.05,
FDR,10%). When we consider the intersection of eQTL-bearing
genes and drug-response correlated genes in each dataset
independently, however, we see that only 1.4% (WTSI) and
0.9% (Broad) of genes are both correlated to drug response and
bear a cis-eQTL. Neither intersection contains more genes than
would be expected by chance alone and, at most, only a small
fraction of genes are involved.
Among the 1000 ‘‘best-measured’’ genes in each RNA dataset,
we identified a total of 23 genes that happened to contain both an
eQTL and showed correlation of RNA levels to drug response. We
asked whether these 23 eQTL SNPs showed a non-random
Figure 4. RNA expression is correlated to SNPs and cellular traits. 198 unrelated individuals were whole-genome RNA profiled on the
Affymetrix platform at the Broad Institute (‘‘Broad RNA’’) and independently on the Illumina platform at WTSI (‘‘WTSI RNA’’). The 1000 ‘‘best-
measured’’ genes identified in Figure 3 were tested for correlation to SNPs and cellular traits. (A) For each tested gene, Broad RNA expression levels
were rank-correlated to copy numbers of EBV, as determined by quantitative PCR. The correlation was expressed as rho
2 and curves representing
distributions of the rho
2values are plotted. The green curve is the observed distribution of EBV-RNA correlations. The red curves represent 20
permuted distributions. The blue curve is the average of permuted distributions. The black curve is the difference between observed and permuted
values and thus a lower bound (see Methods) of the fraction of genes correlated to EBV at a given rho
2. Plot shows that ,15% of expressed genes
have .5% of their (rank) variance in expression explained by EBV levels. (B) For each tested gene, Broad RNA expression levels were correlated to
baseline ATP levels determined by measuring Celltiter glo in mock-treated wells in the drug response assays. Curves representing the distribution of
rho
2 values were plotted for the tested genes as in (A). Plot shows that .25% of expressed genes have .5% of their variance in expression explained
by ATP levels. (C) For each tested gene, Broad RNA expression levels were correlated to all SNPs with MAF.10% within a 0.15 Mb window around the
gene, using the HapMap phase II data. Curves representing the distribution of the largest r
2 value was plotted for each tested genes as in (A). Plot
shows that .9% of genes have .5% of their variance in expression explained by SNPs in the Broad RNA dataset. (D) For each tested gene, Sanger
RNA expression levels were correlated to all SNPs with MAF.10% within a 0.15 Mb window around the gene, using the HapMap phase II data. Curves
representing the distribution of the strongest r
2 value was plotted for each tested genes as in (C). Plot shows that .20% of genes have .5% of their
variance in expression explained by SNPs in the WTSI RNA dataset. (E) For each tested gene, Broad RNA expression levels were correlated to EBV,
growth rate, and relative ATP, and the strongest observed correlation among the 3 phenotypes was plotted. Strikingly, plot shows that .40% of
genes have .5% of their variance in expression explained by one of these covariates. (F) For each tested gene, WTSI RNA expression levels were
correlated to EBV, growth rate, and relative ATP, and the strongest observed correlation among the 3 phenotypes was plotted. Strikingly, plot shows
that the effect of covariates in (E) is observable even when looking at a completely separate expression experiment, performed independently of
covariate collection.
doi:10.1371/journal.pgen.1000287.g004
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RNA expression levels to inter- and intra-individual variation in drug response. Total variance for each of the 1000 ‘‘best-measured’’ genes
was separated into inter- and intra- individual variance components (see Methods) using expression data from the 49 unrelated individuals measured
twice at the Broad Institute on the Affymetrix platform. (A) 95 genes with eQTLs that explained .10% of expression variance (FDR,10%) in the WTSI
dataset were selected (to maximize eQTL detection power) and the SNP genotype was included in the variance components model of the gene to
‘‘account’’ for its effect. 21 times the change in each variance component is plotted for each gene. As expected, the plot shows that that SNPs (which
remain fixed across experiments) only explain inter-individual variation in expression. Grey dashed lines indicate the inter- and intra- 2.5% and 97.5%-
tiles of the distribution of variance component change estimates when the entire analysis is repeated on a permuted dataset. (B) 125 genes
correlated to EBV at rho
2..05 (FDR,10%) were selected and the EBV measurement was included in the variance components model of the gene to
‘‘account’’ for its effect. 21 times the change in each variance component is plotted for each gene. The plot shows that EBV is correlated to inter-
individual differences in gene expression that persist across experiments, intra-individual fluctuation in gene expression between experiments,o r
both, depending on the gene in question. Grey dashed lines are as in (A). (C) 249 genes correlated to ATP at rho
2..05 (FDR,10%) were selected and
the ATP measurement was included in the variance components model of the gene to ‘‘account’’ for its effect. 21 times the change in each variance
component is plotted for each gene. The plot shows that ATP is correlated to inter-individual differences in gene expression that persist across
experiments, intra-individual fluctuation in gene expression between experiments, or both, depending on the gene in question. Grey dashed lines are
as in (A). (D) 202 ‘‘drug-response correlated’’ genes were defined as in Figure 6. The expression of each gene was incorporated in a variance
components model of the assigned drug response EC50 to examine the correlation of the gene to its strongest correlated drug. 21 times the change
in the variance components of drug response is plotted for each gene, showing that it is mostly the inter- individual differences in gene expression
that are correlated to cell line drug response. Grey dashed lines are as in (A).
doi:10.1371/journal.pgen.1000287.g005
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regressed the drug EC50 against genotype for each of the 23 SNPs
above, we saw an excess of association over that expected under
the null distribution (Figure 6). Moreover, the associations of SNPs
with drug response appear to be in the direction predicted by the
pair-wise SNP-RNA and RNA-Drug response relationships
(Figure S3). A simulated dataset with the same SNP/RNA/Drug
variances and independent SNP-RNA/RNA-Drug pairwise co-
variances (i.e. the eQTLB/RNAB scenario in Figure 6A) as those
observed fails to demonstrate the excess association between SNPs
and drug-response (Figure 6B – gray lines). Though no highly
significant examples were documented, these observations are
consistent with the existence of eQTLs associated with drug
response (i.e. the eQTLA/RNAA scenario in Figure 6A).
While Figure 6B might suggest that many eQTLs are associated
with drug response, we recognized a potential bias that might
inflate this association in absence of (or in addition to) real signal:
the ‘‘winner’s curse’’ [36] overestimate of effect size incurred
during discovery of eQTLs (Figure S4). To examine this possible
source of spurious association, we replaced all simulated eQTL
effects in (Figure 6B) with an eQTL whose true effect is r
2=0.05,
but whose observed effect in simulated datasets is r
2.0.08. In this
(more realistic) simulation, we recreate an inflation of p-values
similar to that observed. (Figure 6C). This analysis suggests that
winner’s curse may contribute to the apparent excess of association
in Figure 6B.
Finally, if these eQTLs were truly influencing drug response,
one might expect that stronger eQTLs would have stronger
associations with drug response. We plotted the strength of each
eQTL against the strength of association between the eQTL SNP
and drug response. Counter to expectation, the strongest
associations between SNPs and drug response are observed for
SNPs that are weak eQTLs, while most of the stronger eQTLs
have no association with drug response (Figure 6D). We do
observe three SNPs with relatively strong drug response and RNA
levels association (Figure 6D blue arrow): rs1384804-C8orf70
(Ensembl:ENSG00000104427)-MTX, rs3733041-GLT8D1 (En-
sembl:ENSG00000016864)-5FU, and rs2279195-SH3TC1 (En-
sembl:ENSG00000125089)-Simvastatin with SNP-Drug p-values
of 0.03, 0.05, and 0.02 respectively. While these may be interesting
candidates for follow-up and replication, statistical significance is
extremely weak, and thus much larger sample sizes are required to
achieve genome-wide significance.
Discussion
Recent studies have shown that a subset of genes contain cis-
eQTLs that explain a modest fraction of inter-individual variation
in RNA levels. Other studies used LCLs to perform linkage and
association scans for drug response [26,27,28]. However, few
reports characterize the biological reproducibility of these
phenotypes, and none to our knowledge have characterized their
correlation to in vitro measures such as growth rates, EBV copy
number, and metabolic activity. We document that most traits we
studied, whether drug responses or RNA transcript levels, are only
partially reproducible across experiments, and that more genes are
correlated to cellular growth rate, ATP levels, and EBV copy
numbers than to genetic variants (at comparable fractions of
variance explained). Thus, in addition to issues of statistical power
relative to genetic size of effect (Figure S2), day to day variability in
a trait and confounding factors are major influences on gene
mapping experiments in LCLs.
Consistent with prior reports, our genome-wide association
studies of drug response did not reveal any SNPs associated with
drug response with genome-wide significance. The inability to
detect such SNPs is likely due to lack of power to detect weak
effects with limited sample size (Figure S2) and in the presence of
significant confounding and noise.
Several studies attempted to improve power to discover SNPs
associated with drug response [15,16] by integrating eQTLs and
RNA correlations to drug response [18,19]. Whether these eQTLs
are incidental or actually contributing to drug response depends on
whether the cognate RNAs influence drug response or are merely
correlated to drug response by a non-genetic factor that simulta-
neously affects both phenotypes. Our results fail to show convincing
association of eQTL SNPs with drug response (EC50s adjusted for
growth rate and ATP levels). Moreover, some apparent association
can be attributed to ‘‘winner’s curse’’ (a bias possibly avoidable in the
future with the creation of large cohorts for eQTL discovery). We do
observe three potential associations that may merit future study:
rs1384804 near C8orf70 to MTX, rs3733041 near GLT8D1 to 5FU,
and rs2279195 near SH3TC1 to Simvastatin.
The hallmark of genetic mapping is causal inference: the
interpretation that genetic variants at a particular genomic locus
are influencing a trait of interest. This interpretation requires
confidence that the association between genetic variation and
phenotype is not due to confounding, but rather represents a
causal relationship. In an experimental cross, causal inference is
supported by meiotic randomization and the shared parents of all
offspring. In a genome-wide association study, causal inference can
be supported if the genomic background of study participants is
observed to be null distributed and potential confounders are
eliminated. Our data suggest that GWAS of LCLs need to
carefully consider the major impact of non-genetic confounding in
relation to the documented effects of eQTLs. In addition to
reducing power, confounding by non-genetic factors can cause
spurious associations between cell lines and phenotypes, violating
the conditions under which causal inferences can be made.
A major limitation of our study is the relatively small sample size
of the HapMap samples for performing genome-wide association
studies. As much larger collections of LCLs (such as those proposed
to study cell lines from eight thousand and one-hundred thousand
individuals by the Framingham Heart Study [37] and the National
Children’sStudy[38],respectively)arecurrentlybeingcollected,we
are optimistic that larger studies have potential to map pharmaco-
genetic loci in LCLs. By highlighting these aspects of the LCL
model, as well as pointing to how some of them may be addressed,
we hope to build a stronger foundation on which these important
experiments can be planned and carried out.
Materials and Methods
Cell Culture
EBV-transformed lymphoblastoid cell lines were acquired from
the NHGRI Sample Repository for Human Genetic Research in
frozen aliquots. Cells were thawed in 5 mL culture medium
(RPMI medium 1640 (Invitrogen) supplemented with 10%
FetalPlex (Gemini), 2 mM L-Glutamine (Invitrogen), and 16
penicillin/streptomycin (Invitrogen)). Cell lines were counted daily
using Z2 Coulter Counter (Beckman Coulter) and passaged as
needed to maintain a concentration of 2–561e5 cells/ml at 37 C
in a 95% humidified 5% CO2 atmosphere.
Initially, cells were grown until 561e5 cells/ml were reached in
50 mL total volume. Then, ten identical aliquots were frozen in
1 mL freezing media containing 50% FetalPlex, 40% RPMI 1640
medium, and 10% DMSO (Sigma) at 280 C for 24 hrs and
transferred to liquid nitrogen. These aliquots were used to provide
biologic replicates for the experiments described below.
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PLoS Genetics | www.plosgenetics.org 10 November 2008 | Volume 4 | Issue 11 | e1000287Figure 6. Effect of cis-eQTLs in drug-response correlated genes on drug-response. The 198 unrelated individuals were ranked by RNA
expression value for each of the 1000 ‘‘best-measured’’ genes. These individuals were then ranked by response (growth/ATP- corrected EC50) to each
of the 5 assayed drugs. Rank-correlations (spearman’s rho) were computed for each gene-X-drug pair (100065) and the drug with the strongest
correlation to a given gene was ‘‘assigned’’ to that gene. The 202 genes whose strongest drug correlations exceeded rho
2=.05 (FDR,10%) were
taken as ‘‘drug-response correlated’’ genes. If such a gene also had a cis-eQTL that explained at least 8% (FDR,10%) of its variance, the SNP-RNA-
Drug relationship was considered in the foregoing panels. We considered 23 SNP-RNA-Drug response relationships (14 derived using WTSI RNA
dataset+9 derived using the Broad Institute RNA dataset). (A) Diagram of different relationships between SNPs, RNA levels, and drug response.
Coding SNPs have direct (non-RNA mediated) effects on drug response by altering protein function. No SNPs of this class were found at genome-
wide significance in our GWAS scan. Changes in RNAA influences drug response. An eQTL for one of these RNAs (i.e. eQTLA) is thereby associated with
drug response.Non-genetic confounding factors simultaneously influence RNAB levels and drug response; changes in RNAB do not influence drug
response (this is the expected scenario for most RNAs). Even if levels of these RNAs are associated with eQTLs, these eQTLs are not associated with
drug response. (B) For each SNP-RNA-Drug response relationship (WTSI – red, Broad – green) the drug response was regressed against the eQTL SNP
genotype. P-values are plotted as open circles against their expectation under the null distribution. Black solid line indicates the theoretical flat
uniform distribution expected under the null and black dashed line is the p=.05 one-sided significance threshold for deviation from the null. Grey
lines show equivalent null parameters, but derived from a simulated dataset with the same SNP/RNA/Drug variances and independent SNP-RNA/
RNA-Drug pairwise covariances as the real 23 SNP-RNA-Drug response relationships. Plot shows that the observed p-value distribution for drug-
response regressed against RNA eQTL SNPs exceeds that expected by chance. (C) For each SNP-RNA-Drug response relationship, simulated datasets
were created with the same SNP/RNA/Drug variances and RNA-Drug pairwise covariance as the real 23 SNP-RNA-Drug response relationships, but
with the real SNP-RNA covariances replaced by r
2=0.05. Then, only those simulations where the observed SNP-RNA association exceeded r
2=0.08
were used to plot the median and p=.05 SNP-Drug p-value distributions as in (B) (again, grey solid and grey dashed lines, respectively). Black lines
also as in (B). Plot shows that ‘‘winner’s curse’’ in eQTL discovery leads to an inflation of SNP-Drug associations, in the absence of any RNA influence
on Drug response. (D) For each SNP-RNA-Drug response relationship (WTSI – red, Broad – green), the correlation between SNP and RNA is plotted
against the correlation between SNP and Drug. Most increased association between SNP and Drug response comes from the weaker eQTLs, while
most of the stronger eQTLs have no association with drug response, consistent with the winner’s curse phenomenon displayed in (C). Additionally, 3
SNP-RNA-Drug response relationships emerge that are both relatively strong SNP-RNA and SNP-Drug response associations, indicated by the light
blue arrow.
doi:10.1371/journal.pgen.1000287.g006
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above. Cell lines were counted daily and passaged as need to
maintain a concentration of 4–861e5 cells/ml in 10 mL culture
medium. On experiment day #7, cells were counted and
distributed for use in the various experiments described below.
One cc of culture was used for immediate immunophenotyping via
FACS and Luminex beads. One cc of culture was used for RNA
and DNA extraction using Trizol (Invitrogen) following the
manufacturer’s protocol. The remaining eight cc of culture were
used for drug response assays described below.
Drug Response Assay
The drugs that we studied are bortezomib (courtesy of T.
Hideshima), rapamycin (Biomol), 5-fluorouracil (Sigma), metho-
trexate (Sigma), 6-mercaptopurine (MP Biomedicals), SAHA
(Biovision), and simvastatin (Calbiochem). These drugs were
arrayed in a source plate in the concentrations according to
supplemental figure. The source plate was pinned into each cell
line in duplicate, resulting in each drug concentration being
assayed in each cell lines 4 times.
For drug response assays, LCLs for each cell line were diluted to
161e5 cells/ml, and 25 uL of cell culture were plated into each
well of two white solid flat bottom 384 well plates (Corning cat#
3704) using a microplate dispenser (Multidrop Combi, Thermo
Scientific). Next, 100 nL was pin-transferred from the source
plates into the plates containing cells using an automated 384
channel simultaneous pippettor (CyBi-Well, CyBio). Plates were
incubated at 37 C in a 95% humidified 5% CO2 incubator.
After 48 hrs, plates were removed from the incubator to room
temperature for 10 minutes prior to being vortexed for 30 sec-
onds. 25 uL of Celltiter Glo (Promega Cat No. G7573) diluted 1:3
in PBS was added to each well with the Multidrop microplate
dispenser and shaken for two minutes. Luciferase luminescence
was then immediately measured for each well using a multiplate
illuminometer (Envision, Perkin Elmer). Raw luminescence data is
available online: http://chembank.broad.harvard.edu/assays/
view-project.htm?id=1000477.
The experiment was monitored for cell-culture handling,
plating, pinning, and assay errors and failed cell lines/plates/
drug-rows were excluded from down-stream analysis. (Most cell
lines were successfully assayed on two plates for all drugs, however;
specific counts are below.) Luminescence values in drug-exposed
wells were divided by the median control-well luminescence in the
same plate row (after excluding plate edge wells) to obtain 4
viability fractions per cell line, per drug, per dose, in each
experiment. For evaluation of technical reproducibility, the
median of the 2 fractions on each plate was taken as the cell
line’s response to that dose on that plate. For evaluation of
biological reproducibility and all other analyses, the median of the
4 fractions was taken as that cell line’s response to that dose in the
experiment. Drug responses were examined, and it was noted that
the experiment failed to achieve meaningful cytotoxic response to
rapamycin, with most cell lines reaching a maximum fractional
viability of only ,0.6–0.7, even at highest concentration of drug
assayed. It was concluded that the viability assay was not a
relevant read-out for rapamycin response, and the drug was not
considered in further analyses.
Overall cell line response to a given drug was then calculated by
taking the average response to a dose across all cell lines in the
experimental batch (cell lines were assayed in batches of ,90),
subtracting the average from the value for each cell line, and then
averaging the result for each cell line across all doses. (The 4–5
low-concentration doses where all cell lines had a fractional
viability of ,1 were excluded from the calculation.) In this way,
the (single value) relative response of a given cell line to a drug was
calculated, representing the non-parametric distance of that cell
line’s dose-response curve to the average dose-response curve for
that drug in the experiment. (For the analysis of technical
reproducibility, the calculation was done using only replicate plate
A for all cell lines, and then using only replicate plate B, and the
two values were compared). Quality control then proceeded by
examining the dependence of response on the compound stock
plate from which the drugs were pinned. (Compound stock plates
were prepared with enough drug to run ,20 cell lines and drug
response should be independent of the drug stock.) Indeed, it was
noted that for 5FU, 6MP, Simvastatin, SAHA, and MTX,
dependence on drug stock was weak, while for bortezomib, the
dependence was profound, with large differences in response
between different plates, significantly in excess of the differences
between cell lines on a given plate. Thus, bortezomib was excluded
from further analysis. Though dependence on compound plate for
the other 5 drugs was weak, average response for each compound
stock plate was subtracted from each cell line using that plate (for
each drug independently) and this normalized response was
carried forward.
In summary, after the processing steps above in the main batch
of experiments, 254 cell lines were successfully assayed for
response to 6MP, 256 for MTX, 260 for Saha, 262 for Simva,
and 259 for 5FU. 84 cell lines were then again successfully
measured for all 5 drugs as biological replicates. (For ease of
comparison, technical reproducibility is also reported using only
the two plates from these biological replicate samples.) These
values are available as ‘‘relative responses’’ in the online
supplement. Analyses in Figure 2 use this data for the ,200
successfully measured unrelated individuals, after again centering
within each HapMap panel. Also, the median (non-boundary)
control well luminescence over the two plates for each cell line was
taken as the ‘‘ATP content’’ of the cell line. The value was divided
by 100,000 and centered within each HapMap panel.
Modeling Drug Response
To account for the effect of growth-rate on response to MTX,
5FU, and 6MP, we reasoned as follows: Assume a simple ODE
model of cell line population growth: dP
dt ~rP, where P(t) is the # of
cells in the population at a given time, and r is the (unobserved in
the specific drug-exposure experiment) growth rate parameter.
This ODE has the solution: P(t)=P0e
rt. When the cell line is
exposed to drug, its growth-rate is impaired in a concentration-
dependent manner. Taking inspiration from first-order Michaelis-
Menten kinetics, we can model this as:
dPdrug
dt ~r 1{ ð
Max reduction   ConcDrug ½ 
Concentration for half maximal reduction aka 00EC5000z ConcDrug ½  ÞP, which is
solved by Pdrug t ðÞ ~P0e
r 1{
MaxRed  ConcDrug ½ 
EC50z ConcDrug ½ 

t
. As our observed
luminescences are ratios between drug wells and control wells at
given concentrations, we can write
Pdrug t ðÞ
Pt ðÞ ~
P0e
r 1{
MaxRed  ConcDrug ½ 
EC50z ConcDrug ½ 

t
P0ert ,
which can simplified as
Pdrug t ðÞ
Pt ðÞ ~e
{r MaxRed  ConcDrug ½ 
EC50z ConcDrug ½  t.
There are two identifiable parameters in this model: the
concentration necessary for half-maximal reduction in growth-rate
(EC50) which is independent of growth rate r itself, and r *
maximal reduction of r, a product term dependent on growth rate
whose components cannot be independently estimated. The model
was fit for each cell line, for each drug independently, using
median measurements at all doses. QC was performed by
excluding all models with RSS.0.08. The –r*MaxRed term was
discarded, and the EC50 was carried into further analysis after
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were successfully fit for 5FU, 251 for 6MP, and 255 for MTX.)
Models were also successfully fit to all 84 biological replicates of
6MP and 5FU, and 82 replicates of MTX. ATP correction for
5FU and MTX was then carried out by taking the residuals of the
linear regression DRUG,ATP.
SAHA and Simvastatin were modeled by a standard sig-
moid[39], with response (fractional viability) at a given
dose~Max Inhibitionz 1{Max Inhibition
1zeslope  log dose ðÞ {log EC50 ðÞ ðÞ . Notably, max inhi-
bition and EC50 are not the same as above, here representing a
minimal viability and the concentration at which that minimal
viability is achieved, respectively. Maximum inhibition (aka
minimum viability) were ,0.05 for most cell lines for simvastatin
and varied between ,0.1–0.3 for SAHA. The EC50 was carried
into further analysis after centering the values within each
HapMap panel. Again, QC was performed by excluding all
models with RSS.0.08. (257 cell lines were thus successfully fit for
Saha and 261 for Simvastatin.) Models were also successfully fit to
all 84 biological replicates of Saha and 5FU, and 83 replicates of
Simvastatin. The GWAS for drug response was performed with all
successfully measured individuals, while analyses presented in
Figures 2,5,6 were performed with unrelated individuals only.
Growth Rate Measurements
Each cell line was seeded at a concentration of 261e5 cell/mL in
2 mL. LCLs were counted daily for five consecutive days with an
automated particle counter (Z2 Coulter Counter, Beckman
Coulter). A regression of the form log(conc day i)=r*i+log(conc
day0)wasfitforeachcelllinetoobtainthe estimateofgrowthrater.
QCwas performed byevaluating the95%confidenceintervalofthe
r estimate and rejecting estimates whose interval width exceeded
1.1. Thus, estimates of growth-rate for 237 cell lines were obtained.
These values were normalized within each population for all
analyses. An abbreviated second replicate of the experiment was
repeated on a subset (155) of the cell lines with only the 3
rd day
counts collected to evaluate growth rate reproducibility.
FACS Analysis
From each LCL, ,25,000 cells were incubated with R-
Phycoerythrin–conjugated mouse anti-human antibody to cell
surface markers (CD19, CD20, CD21, CD40, CD58, CD80,
CD86, CD95, CD227, IgD, IgG, IgM, HLA-DQ, HLA-DR, and
IL6R) at 4uC for 30 min. Cells were washed once with PBS and 1%
fetal bovine serum and were fixed with 1% paraformaldehyde. Data
on cell-surface expression in each cell line were acquired using a
fluorescence-activated cell sorter (BD Biosciences FACSCalibur
system). To quantify expression for each LCL, we used flow
cytometry, requiring at least 500 cells per LCL for it to be included
in our analysis.Fluorescence intensity was measured for the anti-cell
surface protein antibody and a control isotype antibody for each
LCL. A marker (and, separately, a control) histogram was created
by placing individual cell measurements into 1,024 equally spaced
intensitybins. Countsinthecontrolhistogramweresubtracted from
the marker histogram to obtained a ‘‘normalized’’ histogram of cell-
counts in each of the 1,024 intensity bins. The average intensity was
then calculated from this normalized histogram and the log of this
value was carried forward into QC as the average normalized
marker expression for that LCL.
QC then proceeded by regressing this marker expression on the
total cell count obtained for that marker within a given
experimental batch of LCLs. (samples were batched by HapMap
panel) We reasoned that if the experiment was successful, there
should be no dependence of cell-surface marker expression on the
quantity of viable cells obtained in the experiment; if there was
such a dependence, the marker expression was likely reading out
handling differences between LCLs, not true, intrinsic differences
in expression. Indeed, by this metric, we found that during the first
batch of experiments that was attempted (for the CEU panel), only
4 markers were successfully measured, while subsequent batches
(YRI+CHB/JPT samples) succeeded for 14 and 9 markers
respectively. In most markers that passed this filter, it was further
noted that a few cell lines showed very low expression, far from the
overall distribution of the values for each batch. While it is
conceivable that these represent true differences, we interpreted
these values as individual LCL measurement failures, and further
truncated the lowest 5% of values within each marker in each
batch. Thus, the final dataset contains measurements of: 85 cell
lines for CD19 and CD20, 169 for CD21, 166 for CD227, 248 for
CD40, 164 for CD58, 166 for CD80 and CD86, 248 for CD95, 80
for HLADQ, 85 for HLADR and IgM, and 165 for IgD, IgG, and
IL6R. These values were centered within each panel and carried
into further analysis.
Luminex Assay
30 HapMap cell lines were screened with a multiplex antibody
bead kit from Biosource (Cytokine 25-Plex for Luminex (Catalog
#LHC0009)). Of the 25 cytokines originally selected for this assay,
8 were reliably detectable (lower concentration: IL8, IL10,
IL12p40, TNFa, IP10; moderate concentration: MIP1a, MIP1b,
RANTES). Of these, it was found that measurements for MIP1a
and MIP1b were strongly correlated; thus we decided to include
only MIP1b in further experiments. These 7 cytokines were assayed
intheremainder ofthecell lines accordingtothefollowingprotocol:
One cc for each LCL was placed into a single well of 96-deep
well plate. The samples were centrifuged at 500 rpm for 5 minutes
at room temperature. The supernatant was placed into a new 96-
well plate, and placed dry ice to be stored at 280 degrees All
assays were performed on a single thaw.
The cytokines were measured following the manufacturer’s
protocol. In order to ensure that the measured cytokine
concentration fell in the linear part of the standard curve, the
lower concentration cytokines were multiplexed together (final
dilution 1:2); and MIP1b and RANTES were multiplexed together
(final dilution 1:6).
The concentration of each cytokine was calculated based on the
standard curve generated by the same plate, after subtracting out
the ‘‘blank’’ background. A 3-parameter model was used to
convert median fluorescent intensity (MFI) to protein concentra-
tion (ng/ml). A subsequent correction was applied to account for
the dilution factor at the time of the assay. All final concentrations
are expressed as pg/ml and log-transformed. 262 cell lines were
successfully measured for IL10, IL12, IL8, IP10, and TNFa, and
266 measurements were obtained for MIP1b and RANTES. (79
and 87 biological replicate measurements were also obtained for
the above two sets of cytokines respectively.)
RNA Preparation and Affymetrix Expression Profiling
All LCLs were cultured in the fashion described above. Prior to
the plating of cells for the Drug Response Assay, 5610
5 cells were
set aside for RNA extraction. Cells were immediately lysed with
Trizol Reagent (Invitrogen). RNA was collected according to the
manufacturer instructions. 1.25 ug total RNA (OD.1.8) was
diluted to a total volume of 10 uL. RNA was processed and
hybridized onto Affymetrix Human U133A whole genome RNA
expression genechip arrays according to the manufacturer’s
protocol. Gene expression summary values for the whole dataset
were computed by RMA[40,41] and log-transformed. Measure-
ments were successfully obtained for 257 HapMap cell lines in the
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originally thawed at the WTSI, as well as multiple replicates of 5
cell lines derived from chimpanzees. (Expression data is available
on GEO Accession # GSE11582).
For analysis, the dataset was further processed as follows: 1) The
,22 K total probe sets on the Affymetrics U133A were restricted to
the 9084 judged expressed (p-value,0.06) by the Affymetrix software
inatleast2/3of50randomlyselected scans.2)These9084expressed
probes were matched by Genbank transcript accession number
(NM_#) to the 13,300 targets judged expressed by the same criterion
in the WTSI Illumina HapMap experiments (using the probability of
detection p-value output by the Illumina software.) This yielded a
reduced set of 3600 Affymetrix probes (3592 Illumina targets) whose
transcripts were reliably detectable in both experiments. 3) To obtain
a comparable dataset from the WTSI Illumina data, we took the
median over their 4 technical replicates for each target and quantile
normalized across all samples. 4) We averaged within each gene
symbol, in each dataset, for each sample, to get the set of 3538 genes
e x p r e s s e di nb o t he x p e r i m e n t sa n dm e a s u r e do nb o t hp l a t f o r m s .5 )
To prevent family structure from introducing bias, the dataset was
restrictedtounrelatedindividualsonlyfortheanalysesinFigures3–6:
198 each in the main Broad and WTSI experiments, 49 biological
replicates at the Broad, and 16 samples for whom RNA was extracted
at the WTSI and measured in both locations. Both centered (for each
gene within each panel) and uncentered data is available in http://
www.broad.mit.edu/mpg/pubs/hapmap_cell_lines/ and were each
used as appropriate.
Relative EBV and mtDNA Copy Number
All previously collected DNA was diluted to PCR concentration of
2.5 ng/uL and arrayed in 384 well storage plates (AbGene Cat
No. AB-0564). Custom TaqMan assays were designed using Primer
3 (http://frodo.wi.mit.edu/) and ordered from Applied Biosystems.
T h eE B Vc o p yn u m b e ra s s a yi n t e r r o g a t e da6 6 _ b pf r a g m e n ta tt h e
DNA polymerase locus (EBV forward primer 59GACGA
TCTTGGCAATCTCT39, EBV reverse primer 59TGGTCATG-
GATCTGCTAAACC39,E B Vp r o b e5 96FAM-CCACCTC-
CACGTGGATCACGA-MGBNFQ39). The mtDNA copy number
assay examined a 72 bp fragment at the ND2 locus (mtDNA forward
primer TGTTGGTTATACCCTTCCCGTACTA, mtDNA re-
verse primer CCTGCAAAGATGGTAGAGTAGATGA, mtDNA
probe sequence 596FAM-CCCTGGCCCAACCC-MGBNFQ39).
As an internal reference, a 90 bp assay from the NRF1 locus on
chromosome 7 was multiplexed with EBV or mtDNA (NRF1
forward primer 59CTCGGTGTAAGTAGCCACAT 39, NRF1
reverse primer 59GAGTGACCCAAACCGAACAT 39, NRF1
probe 59VIC-CACTGCATGTGCTTCTATGGTAGCCA-
MGBNFQ 39). Equal efficiency of amplification was observed for
each assay in the multiplex reaction. Final Concentrations for EBV
primers, mtDNA primers, EBV probe, mtDNA probe, NRF1
primers and NRF1 probe were .25 uM, .25 uM, 10 uM, 10 uM,
1 uM and 10 uM respectively. 5 ng of DNA template was used for
each TaqMan reaction performed according to the manufacturer’s
protocol. Relative EBV and mtDNA copy number was determined
by the difference of CT method[42]. Log-transformed. EBV
measurements were obtained when cell lines were first received
from Coriell (257), during the main batch of experiments (257), and
for the biological replicate set (86). Mitochondrial DNA measure-
ments were obtained only for 252 cell lines in the main experiments.
Fraction of RNA Variance Explained by Cellular
Phenotype or eQTL (Figure 4)
We are interested in the fraction of gene-trait (or gene-eQTL)
relationships that are real (i.e. would reach statistical significance
given enough samples) and above a given r
2 thresh-hold in the
current sample. So, we want P(real, r
2 .=c) in joint distribution
notation, i.e. a relationship can be real (non-null) or spurious (null)
and can exceed a certain threshold or not. By regressing a trait on
multiple genes, we observe: P(r
2 .=c). It is the fraction of
relationships exceeding any given threshold, the green curve. By
permutation, we also have: P(r
2 .=c|not_real), the blue (average of
black) curve. So, we write, by conditioning on whether a
relationship is real or not:
Pr 2 w~ c

~
~Pr 2 w~ c real j

P real ðÞ zPr 2 w~ c not real j

1{P real ðÞ ðÞ
~P real, r2 w~ c

zPr 2 w~ c not real j

1{P real ðÞ ðÞ :
Or, rewriting, we have:
P real, r2 w~ c

~Pr 2 w~ c

{Pr 2 w~ c not real j

1{P real ðÞ ðÞ :
Everything on the right hand side is known, except P(real), the true
proportion of gene-trait relationships in the data. This can
theoretically be estimated ala Storey et al. 2003 [43] but the
estimate can be unreliable in the setting of dependencies, as is the
case in our data since genes are largely in clusters. So, we take the
worst case scenario, setting P(real)=0. Thus, we have:
P real, r2 w~ c

§Pr 2 w~ c

{Pr 2 w~ c not real j

:
So, P(r
2 .=c)2P(r
2 .=c|not_real) is then a lower bound for P(real,
r
2.=c), the black curve. It is important to note that the
interpretation of this lower bound is limited to the sample size
used in the analysis. Given more samples, the estimate will change
to even more genes being affected by traits or eQTLs, albeit at
lower r
2s.
Decomposing Gene Expression into Inter- and Intra-
Components (Figure 5)
To estimate the amount of inter- and intra- individual variation
present for each gene in the ,50 unrelated individuals thawed and
measured twice at the Broad Institute, we fit a random effects
model of the form yij=m+ai+eij, where i indexes the individuals,
and j is 1 or 2 for the biological replicate being considered. The
estimated variance component s2
a is then the inter-individual
variation in gene expression for the gene, while the residual
variance s2
e is the intra-individual variation. To evaluate the effect
of a cis-eQTL or cellular phenotype on an RNA, a fixed effect x
corresponding to trait was then added to the model to get:
yij=m+bxij+ai+eij. The resultant change in variance components
s2
a and s2
e can then be interpreted as the ‘‘effect’’ of that trait or
snp on RNA expression. The directionality of the effect is clearly
only known for SNPs, but the nature of relationship (inter-, intra-,
or both) can be examined for any trait. It’s worth pausing to reflect
on what these ‘‘effects’’ mean: If including a QTL SNP genotype
in the model reduces inter-individual variance (as the overwhelm-
ing majority of SNPs do, Figure 5A), it implies that fixed
differences in genotypes (QTLs) between individuals correlate to
fixed differences in expression between individuals in the
corresponding gene. (as one would expect) If, on the other hand,
the intra-individual variance component is reduced when
accounting for a given trait, the implication is that day-to-day
variations in the trait correspond to day to day variations in the
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of the two effects. Finally, these estimates are quite noisy, suffering
from random fluctuations in RNA levels, measurement error, and
the relatively small sample size available for the analysis;
estimation is likely even less reliable for weaker effects.
Nevertheless, the analysis is instructive for the stronger signals
and overall patterns and would improve given more samples and
technical replicates.
GWAS for Drug Response
1,045,141 autosomal SNPs with MAF.10% in each of the 3
(CEU, YRI, CHB/JPT) HapMap panels were selected from the
Phase 2 HapMap build 21 for association testing to drug response
phenotypes. The between/within family model of association was
tested for each SNP against each drug, in each panel indepen-
dently, using PLINK[32] v1.02 with options ‘‘–qfam-total –geno 1
–aperm 100 100 000 000 0.00000005 0.0001 5 0.001’’. For each
drug, p-values for each SNP were then combined across panels
using Fisher’s method. 25,735 X-chromosome SNPs were tested
analogously, but using an additive model on unrelated individuals
only with PLINK command line ‘‘–assoc –geno 1’’; none exceeded
5e-8. QQ plots for the autosomal SNPs for each drug are available
at: http://www.broad.mit.edu/mpg/pubs/hapmap_cell_lines/
snps_vs_drug_response_pvalues/.
R – Aside from GWAS scans performed using PLINK, all other
analyses were performed using R version 2.5.0[44].
Supporting Information
Figure S1 Heritability power estimate. A power calculation was
performed for the growth-rate and ATP level heritability estimates
using the R package pwr (v1.1). Power to detect narrow-sense
heritability (h
2) is plotted as a function of heritability. The
significance threshold (alpha) is set to 0.05. Sample sizes of the
power calculation are set to the number of fully phenotyped trios
used in the heritability estimates: N=51 for ATP level and N=37
for growth rate. The following assumptions were made in the
power calculation: s
2
mother=s
2
father=s
2
offspring=1; covarian-
ce(offspring, mother)=covariance(offspring, father); covariance
(mother, father)=0. Plot shows that the heritability estimates are
not well-powered to detect heritability,0.5.
Found at: doi:10.1371/journal.pgen.1000287.s001 (0.01 MB PDF)
Figure S2 Drug response GWAS power estimate. A power
calculation was performed for the drug response GWAS using the
R package pwr (v1.1). Power to discover a QTL is plotted as a
function of the fraction of variance in drug response the putative
QTL explains. The significance threshold (alpha) is set to the
genome-wide significance level of 5e-8. As the GWAS was
performed in trios, two estimates are plotted: (1) a lower bound
on power corresponding to the scan including only successfully
measured unrelated individuals (i.e., no useful information from
trio kids has been derived); and (2) an upper bound on power
corresponding to trio kids providing as much information as
another unrelated individual. As trio kids actually provide an
intermediate amount of extra information, true power of the study
lies between the two bounds. Plot shows that the GWAS is only
well-powered to detect strong (.15% variance explained) drug
response QTLs.
Found at: doi:10.1371/journal.pgen.1000287.s002 (0.01 MB PDF)
Figure S3 Direction of SNP-Drug response association. For
each tuple (WTSI – red, Broad – green) in Figure 6, the product of
the correlation (r) between SNP and RNA and the correlation
(rho) between RNA and Drug is plotted against the correlation (r)
between SNP and Drug. Black lines separate the plot into the 4
quadrants. Gray dotted lines show the expected distribution of
associations between SNP and Drug under the ‘‘null’’ model
simulated in Figure 6B. Plot shows that the direction of association
SNP-Drug response tends toward the direction predicted from the
directions of the SNP-RNA and RNA-Drug correlations (i.e., if the
major allele drives the RNA up and more RNA makes the cell-line
more sensitive to drug, then the major allele should make the cell-
line more sensitive to drug). This tendency would not be expected
by chance alone.
Found at: doi:10.1371/journal.pgen.1000287.s003 (0.01 MB PDF)
Figure S4 Winner’s curse in eQTL discovery. Simulations were
performed to demonstrate that effect sizes of weaker eQTLs are
overestimated, on average. Specifically, for effect sizes (r
2) between
0.01 and 0.50, 100,000 datasets of 198 values each (corresponding
to the sample size of the analysis in Fig. 6) were simulated from a
bivariate normal distribution with mean=(0,0), variances=(1,1)
and covariances=sqrt(effect size). Datasets with observed corre-
lation (r
2).0.08 were then considered: For each simulated effect
sizes, the average difference (bias) between the observed and
simulated effect size is plotted, together with the standard
deviation of the distribution of differences. Plot shows that weaker
eQTLs are usually over-estimated, even for true effects that are
above the detection threshold. On the other hand, estimates of
effect sizes of stronger eQTLs are unbiased, on average.
Found at: doi:10.1371/journal.pgen.1000287.s004 (0.14 MB PDF)
Table S1 Correlation between relative drug responses on
replicate plates.
Found at: doi:10.1371/journal.pgen.1000287.s005 (0.13 MB PDF)
Table S2 Correlation between relative drug responses in
independent experiments.
Found at: doi:10.1371/journal.pgen.1000287.s006 (0.12 MB PDF)
Table S3 Correlation between relative drug responses and
growth rates.
Found at: doi:10.1371/journal.pgen.1000287.s007 (0.17 MB PDF)
Table S4 Correlation between growth-rate corrected EC50s for
each of the drugs and growth rates.
Found at: doi:10.1371/journal.pgen.1000287.s008 (0.17 MB PDF)
Table S5 Correlation between growth-rate and ATP-corrected
EC50s for each of the drugs.
Found at: doi:10.1371/journal.pgen.1000287.s009 (0.15 MB PDF)
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